Table 1.

Clinicopathological parameters of GBC patients.

Clinical features	Control group (N = 43)		HIPEC group (N = 35)		P value
	N	%	N	%
Age (years)					0.666
≤60	20	46.51	18	51.43
>60	23	53.49	17	48.57
Gender					0.915
Female	29	67.44	24	68.57
Male	14	32.56	11	31.43
Stones					0.222
Negative	15	34.88	17	48.57
Positive	28	65.12	18	51.43
Tumor location					0.967
Bottom and body of gallbladder	26	60.47	21	60.00
Gallbladder neck and cystic duct	17	39.53	14	40.00
CEA					0.177
Normal	28	65.12	24	68.57
High	15	33.88	11	31.43
CA19-9					0.156
Normal	24	55.81	25	71.43
High	19	44.19	10	28.57
CA125					0.872
Normal	29	67.44	23	65.71
High	14	32.36	12	34.29
CA242					0.995
Normal	27	62.79	22	62.86
High	16	37.21	13	37.14
Lymph node metastasis					0.906
Negative	24	55.81	20	57.14
Positive	19	44.19	15	42.86
Microvascular infiltration					0.369
Negative	32	74.42	29	82.86
Positive	11	25.58	6	17.14
Nerve invasion					0.956
Negative	28	65.12	23	65.71
Positive	15	34.88	12	34.29
Body surface area (m2)	1.54 ± 0.49		1.58 ± 0.35		0.492
Tumor size (cm)	3.6 ± 1.6		4.1 ± 1.4		0.109
Operation time (minutes)	335 ± 103		350 ± 65		0.586
Hospital stay (days)	20.0 ± 5.8		23.0 ± 6.9		0.029∗

Note: χ2 test was used to compare the distribution of clinical features between control group patients and HIPEC group patients. CA19-9 normal reference range: 0–35 U/mL. CA242 normal reference range: 0–20 U/mL. CEA normal reference range: 0–5 ng/mL. CA125 normal reference range: 0–35 U/mL. ^∗P value < 0.05 was considered significant.